The center now houses the research activities of ImClone Systems, a wholly owned subsidiary of Lilly (Lilly acquired ImClone in 2008) along with certain rights to already-marketed Erbitux and ImClone's pipeline of oncology biologics.
The new science park, located next to the NYU Langone Medical Center at 560 First Avenue at 33rd Street, will also house ImClone's Research Division, which is owned by Eli Lilly, the company said in a press release.
ImClone Systems Incorporated (NASDAQ: IMCL), has seen global net sales of Erbitux for the fourth quarter of 2007 increase to $371 million, compared with $293 million in the fourth quarter of 2006, up 27%.
Repligen Corporation (Waltham, MA) has reached a settlement with ImClone Systems in the lawsuit against ImClone for infringement of United States Patent 4,663,281 based on ImClone's manufacture and sale of Erbitux.
ImClone Systems Incorporated (NASDAQ: IMCL) and UCB have entered into a worldwide strategic partnership for the development and commercialization of CDP-791, a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being developed by UCB.